8-KRegulation FDExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Mar 7, 2012)

Filed March 7, 2012For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on March 7, 2012, to update its financial guidance for the year ending December 31, 2012. The company now anticipates concluding 2012 with over $250.0 million in cash, cash equivalents, and marketable securities. This upward revision in cash guidance was announced in conjunction with a company overview presentation at the Cowen and Company 32nd Annual Health Care Conference. Investors should note that this information was presented via a slide deck, which is incorporated by reference in the filing. While the increase in cash is a positive indicator of financial health and operational runway, the filing also includes standard forward-looking statement disclaimers, reminding investors of the inherent risks in drug development, regulatory processes, intellectual property, competition, and funding. The company explicitly states it has no obligation to update these forward-looking statements.

Key Highlights

  • 1Alnylam Pharmaceuticals updated its 2012 year-end cash guidance upwards.
  • 2The company now expects to end 2012 with greater than $250.0 million in cash, cash equivalents, and marketable securities.
  • 3This updated guidance was presented at the Cowen and Company 32nd Annual Health Care Conference.
  • 4A slide presentation detailing the company overview and updated guidance was filed as Exhibit 99.1.
  • 5The filing includes standard forward-looking statement disclaimers, highlighting risks in drug development, regulatory approvals, and competition.
  • 6The company will not provide updates to forward-looking statements unless legally required.

Frequently Asked Questions

The primary purpose of this 8-K filing is to update Alnylam Pharmaceuticals' previously issued cash guidance for the fiscal year ending December 31, 2012. The company now projects a stronger cash position than previously indicated.

Alnylam Pharmaceuticals now expects to end the year 2012 with greater than $250.0 million in cash, cash equivalents, and marketable securities.

The updated cash guidance was announced in connection with a company presentation at the Cowen and Company 32nd Annual Health Care Conference on March 7, 2012. The accompanying slide presentation was filed as an exhibit.

The filing reiterates typical risks associated with biotechnology companies, including challenges in drug discovery and development, efficacy and safety demonstration, regulatory hurdles, intellectual property protection, competition, funding needs, and reliance on third parties. Investors are advised to refer to the company's most recent 10-K for a more detailed discussion of these risks.